Growth Metrics

Novartis Ag (NVS) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Novartis Ag (NVS) over the last 16 years, with Q1 2024 value amounting to -$23.0 million.

  • Novartis Ag's Other Accumulated Expenses fell 36000.0% to -$23.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was -$23.0 million, marking a year-over-year decrease of 36000.0%. This contributed to the annual value of $516.0 million for FY2023, which is 3827.75% down from last year.
  • Novartis Ag's Other Accumulated Expenses amounted to -$23.0 million in Q1 2024, which was down 36000.0% from $516.0 million recorded in Q4 2023.
  • Novartis Ag's Other Accumulated Expenses' 5-year high stood at $836.0 million during Q4 2022, with a 5-year trough of -$113.0 million in Q3 2021.
  • In the last 5 years, Novartis Ag's Other Accumulated Expenses had a median value of $137.0 million in 2021 and averaged $306.3 million.
  • As far as peak fluctuations go, Novartis Ag's Other Accumulated Expenses skyrocketed by 46371.68% in 2022, and later crashed by 36000.0% in 2024.
  • Quarter analysis of 5 years shows Novartis Ag's Other Accumulated Expenses stood at $749.0 million in 2020, then decreased by 17.36% to $619.0 million in 2021, then skyrocketed by 35.06% to $836.0 million in 2022, then crashed by 38.28% to $516.0 million in 2023, then plummeted by 104.46% to -$23.0 million in 2024.
  • Its last three reported values are -$23.0 million in Q1 2024, $516.0 million for Q4 2023, and -$5.0 million during Q1 2023.